Download Protocol

PT-141 (Bremelanotide)

PT-141 is a synthetic peptide studied for its effects on sexual desire and arousal. Unlike medications that work by increasing blood flow, PT-141 works directly on the brain to enhance sexual motivation. It is approved as Vyleesi for specific clinical use but is also researched for broader potential effects in both men and women.

Description

• PT-141 (Bremelanotide) is a melanocortin receptor agonist derived from Melanotan II.
• Stimulates neural pathways that regulate libido and arousal.
• FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women under the brand name Vyleesi.

How It Works

• Activates melanocortin receptors MC3R and MC4R in the central nervous system.
• Influences sexual arousal and desire independently of hormone levels.
• Does not rely on blood vessel dilation like PDE5 inhibitors (e.g., Viagra).

Documented Effects

• Increases sexual desire and response in both men and women in controlled trials.
• Onset typically 30–60 minutes post-injection, lasting 6–12 hours.
• Improved satisfaction and arousal reported in female HSDD research.

Theoretical Effects

• May enhance emotional connection, mood, and intimacy through neural activation.
• Explored for potential use in antidepressant-related sexual dysfunction and general libido support.
• Not intended for chronic or daily use; effects are episodic.

Pharmacokinetics

• Half-life: ~2.5 hours (subcutaneous route).
• Onset: 30–60 minutes after administration.
• Duration: 6–12 hours for central effects.

Reconstitution

• Use only bacteriostatic water for reconstitution.
• Example vial: 10 mg of PT-141
• Choose reconstitution volume based on dosing preference:
  • 1 mL → 10 mg/mL → 1 mg per 10 units
  • 2 mL → 5 mg/mL → 500 mcg per 10 units
  • 4 mL → 2.5 mg/mL → 250 mcg per 10 units
• Swirl gently to dissolve; do not shake.
• Refrigerate reconstituted solution (2–8 °C). Use within ~25 days for best stability.

Injectable Dosage Overview (Research Reference)

Typical Starting Dose

• 250–500 mcg subcutaneous (SC), 45–60 minutes before desired effect.
• Start low to assess tolerance; nausea may occur at higher doses.

Common Research Range

• 500–1000 mcg SC per dose.
• Effects typically appear within one hour and can persist for several hours.

Maximum Recommended Range

• Up to 2 mg within 24 hours (based on approved product data).
• Doses spaced at least 48–72 hours apart reduce risk of side effects.

Standard Cycle Length

• Situational use as needed; not a daily protocol.
• No benefit demonstrated with continuous use over time.

Clinical Notes

• Administer subcutaneously, typically in the lower abdomen; rotate sites to prevent irritation.
• Onset often occurs within 1–4 hours, with effects lasting up to 12–24 hours depending on individual sensitivity.
• Can cause flushing, nausea, or warmth shortly after injection—dose-dependent and usually transient.
• More effective when taken on an empty stomach, as gastric peptides and insulin may slightly blunt CNS response.
• Should not be combined with alcohol in high amounts, as it may intensify hypotension or nausea.
• Stable for about 25 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes

• Most common side effects: mild nausea, flushing, headache, increased blood pressure.
• Avoid use with alcohol or vasoconstrictive medications.
• Maintain sterile technique and verify compound source and purity.